BACKGROUND: To investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose. METHOD: Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively. RESULTS: All 32 patients underwent laparotomy including 18 (56.3%) pancreaticoduodenectomy (PD), six (18.7%) segmental resection (SR), and eight bypass procedures. And R0 resections were obtained in 22 patients; the other ten procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 78.1% (25/32), 43.8% (14/32), and 18.8% (6/32), respectively; moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (20/20), 70.0% (14/20), and 30.0% (6/20), which were significantly higher than those (41.7% = /12, 0%, and 0%) in patients with palliative operation (P < 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05). CONCLUSION: PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients especially for tumors of the distal duodenum.
BACKGROUND: To investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose. METHOD: Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively. RESULTS: All 32 patients underwent laparotomy including 18 (56.3%) pancreaticoduodenectomy (PD), six (18.7%) segmental resection (SR), and eight bypass procedures. And R0 resections were obtained in 22 patients; the other ten procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 78.1% (25/32), 43.8% (14/32), and 18.8% (6/32), respectively; moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (20/20), 70.0% (14/20), and 30.0% (6/20), which were significantly higher than those (41.7% = /12, 0%, and 0%) in patients with palliative operation (P < 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05). CONCLUSION:PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients especially for tumors of the distal duodenum.
Authors: Juan Manuel Ramia; Jesús Villar; Antonio Palomeque; Karim Muffak; Alfonso Mansilla; Daniel Garrote; José Antonio Ferrón Journal: Cir Esp Date: 2005-04 Impact factor: 1.653
Authors: F G Bakaeen; M M Murr; M G Sarr; G B Thompson; M B Farnell; D M Nagorney; D R Farley; J A van Heerden; L M Wiersema; C D Schleck; J H Donohue Journal: Arch Surg Date: 2000-06
Authors: D Dorcaratto; H M Heneghan; B Fiore; F Awan; D Maguire; J Geoghegan; K Conlon; E Hoti Journal: J Gastrointest Surg Date: 2015-01-17 Impact factor: 3.452
Authors: Edwin O Onkendi; Sarah Y Boostrom; Michael G Sarr; Michael B Farnell; David M Nagorney; John H Donohue; Michael L Kendrick; Kaye M Reid-Lombardo; William S Harmsen; Florencia G Que Journal: J Gastrointest Surg Date: 2012-02-17 Impact factor: 3.452
Authors: Maryam Zenali; Michael J Overman; Asif Rashid; Russell B Broaddus; Hua Wang; Matthew H Katz; Jason B Fleming; James L Abbruzzese; Huamin Wang Journal: Hum Pathol Date: 2013-10-15 Impact factor: 3.466
Authors: Valentina Lancellotta; Giuseppe Russo; Marco Lupattelli; Martina Iacco; Elisabetta Perrucci; Claudio Zucchetti; Lorenzo Falcinelli; Cynthia Aristei Journal: World J Gastrointest Oncol Date: 2017-02-15